BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Xenophon Asvos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Materials Science and Engineering, University of Ioannina, Ioannina 45110, Greece. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Nuclear Receptor Subfamily 4, Group A, Member 2, Retinoid X Receptor alpha. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Secretariat for Research and Innovation, Michael J. Fox Foundation for Parkinson's Research, Seventh Framework Programme.
Abstract (Originalsprache)
We report the discovery of a Nurr1-RXRα heterodimer-selective rexinoid which emerged from the structural modification of aminopyrimidine XCT0135908. Although XCT0135908 demonstrated high selectivity for the Nurr1-RXRα heterodimer over other RXRα dimerization partners, its poor in vivo stability and limited brain penetration hindered its utility. Structure-activity relationship (SAR) studies alongside bioactivity evaluations of a diverse series of substituted pyrimidines led to BRF110, a brain-penetrant compound retaining the selective activation of the Nurr1-RXRα heterodimer. BRF110, as XCT0135908, protects dopaminergic cells against the Parkinson's disease-related toxin MPP+ and increases BDNF transcription in mice. Notably, BRF110, in contrast to the market-approved pan-RXR agonist bexarotene, did not elevate triglyceride levels, indicating that enhanced heterodimer selectivity can mitigate off-target in vivo side effects of rexinoids. These findings highlight the potential of heterodimer-selective scaffolds as a strategy for improving the therapeutic profile of rexinoids, addressing significant challenges in the clinical development of RXR-targeting molecules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Materials Science and Engineering, University of Ioannina, Ioannina 45110, Greece.
- Department of Pharmacy, University of Patras, Patras 26504, Greece.
- Center for Clinical Research, Experimental Surgery, and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens 11527, Greece.
- Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens 15341, Greece.
ORCID-Profile: Constantin Tamvakopoulos, Athanasios Papakyriakou, Demosthenes Fokas
Förderung
- General Secretariat for Research and Innovation
- Michael J. Fox Foundation for Parkinson's Research
- Seventh Framework Programme
Zitieren
APA
Asvos, X., El Mubarak, M. A., Karampelas, T., Rampias, T., Tamvakopoulos, C., Sivolapenko, G. B., Papakyriakou, A., Topouzis, S., Vassilatis, D. K., & Fokas, D. (2025). BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03046
Vancouver
Asvos X, El Mubarak MA, Karampelas T, Rampias T, Tamvakopoulos C, Sivolapenko GB, et al. BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03046
BibTeX
@article{Asvos2025,
author = {Asvos, Xenophon and El Mubarak, Mohamed A and Karampelas, Theodoros and Rampias, Theodoros and Tamvakopoulos, Constantin and Sivolapenko, Gregory B and Papakyriakou, Athanasios and Topouzis, Stavros and Vassilatis, Demetrios K and Fokas, Demosthenes},
title = {BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03046}
}
EUVIMED